Plant-derived secondary metabolites and nanotechnology: innovative strategies and emerging challenges in myocardial ischemia-reperfusion injury therapy
Frontiers in Pharmacology · 29.05.2025 · 16
DOI: 10.3389/fphar.2025.1529478 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.05.2025. Verfasst von Wei Shi und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Second Department of Critical Care Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Therapy for acute myocardial infarction often causes myocardial ischemia-reperfusion injury (MIRI), which is characterized by oxidative stress, inflammation, and apoptosis. Traditional therapies have shown poor effectiveness because of their low absorption and inappropriate targeting. Recently, nanotechnology has emerged as a promising treatment option for MIRI. Nanocarriers, such as liposomes, polymers, inorganic nanoparticles, and hybrid nanoparticles, make therapies more effective by making drugs more stable, improving targeting accuracy and lowering side effects. Plant-derived secondary metabolites and nanoparticles, specifically those containing Panax notoginseng saponins and flavonoids, have been shown to work together as a therapeutic approach. These nanoparticles have antioxidant, anti-inflammatory, and anti-apoptotic properties that significantly reduce myocardial injury after reperfusion. Targeting specificity and safety limit clinical translation, even with significant technological developments in these areas. Herein, we review current studies on nanocarriers and plant-derived secondary metabolite nanoparticles for MIRI treatment, as well as potential future clinical applications and limitations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Second Department of Critical Care Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
- Laboratory of Cardiopulmonary Resuscitation and Critical Care, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
- National Clinical Research Center for TCM Cardiology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
- Key Laboratory of Disease and Syndrome Integration Prevention and Treatment of Vascular Aging, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Zitieren
APA
Shi, W., Xu, Y., Wei, J., Zhang, X., Zhu, S., Guo, H., Huang, Q., Qi, C., Hua, T., Liu, Y., & Yang, M. (2025). Plant-derived secondary metabolites and nanotechnology: innovative strategies and emerging challenges in myocardial ischemia-reperfusion injury therapy. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1529478
Vancouver
Shi W, Xu Y, Wei J, Zhang X, Zhu S, Guo H, et al. Plant-derived secondary metabolites and nanotechnology: innovative strategies and emerging challenges in myocardial ischemia-reperfusion injury therapy. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1529478
BibTeX
@article{Shi2025,
author = {Shi, Wei and Xu, Yang and Wei, Jian and Zhang, Xiaoyu and Zhu, Shuaijie and Guo, Heng and Huang, Qihui and Qi, Chuyao and Hua, Tianfeng and Liu, Yue and Yang, Min},
title = {Plant-derived secondary metabolites and nanotechnology: innovative strategies and emerging challenges in myocardial ischemia-reperfusion injury therapy},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1529478}
}
EUVIMED